Literature DB >> 3438666

The AHA syndrome: arthritis, hives and angioedema.

D J McNeil1, T D Kinsella, A M Crawford, M J Fritzler.   

Abstract

Nine patients who have intermittently exhibited the concurrent triad of arthritis or arthralgia (A), hives or urticaria (H) and angioedema (A), in the absence of associated infection or connective-tissue disease, are reported. The ratio of women to men is 4:1, with no apparent age specificity. The duration of the disease has been up to 16 years, with an average of seven acute episodes per year, lasting up to 14 days. Upper-airway angioedema has been severe in four patients. Routine laboratory studies were normal, as were studies of complement levels, and both humoral and cellular immunity. Two samples of synovial fluid from one patient contained a marked preponderance of Ia-positive macrophages. The absence of associated infection and connective-tissue disease suggests this recurrent triad represents a distinct entity, which is designated the AHA syndrome.

Entities:  

Mesh:

Year:  1987        PMID: 3438666     DOI: 10.1007/BF00270529

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

1.  Serum complement and immunoglobulin levels in sporadic and familial ankylosing spondylitis.

Authors:  T D Kinsella; L Espinoza; F B Vasey
Journal:  J Rheumatol       Date:  1975-09       Impact factor: 4.666

2.  Functional analysis of human T cell subsets defined by monoclonal antibodies. V. Suppressor cells within the activated OKT4+ population belong to a distinct subset.

Authors:  Y Thomas; L Rogozinski; O H Irigoyen; H H Shen; M A Talle; G Goldstein; L Chess
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

3.  Cooperation between mononuclear phagocytes and lymphocytes in immunity.

Authors:  E R Unanue
Journal:  N Engl J Med       Date:  1980-10-23       Impact factor: 91.245

4.  Eosinophilic synovial effusions complicating chronic urticaria and angioedema.

Authors:  R W Klofkorn; T J Lehman
Journal:  Arthritis Rheum       Date:  1982-06

5.  The macrophage as an effector cell.

Authors:  C F Nathan; H W Murray; Z A Cohn
Journal:  N Engl J Med       Date:  1980-09-11       Impact factor: 91.245

6.  Histamine stimulates prostaglandin E production by rheumatoid synovial cells and human articular chondrocytes in culture.

Authors:  D J Taylor; J R Yoffe; D M Brown; D E Woolley
Journal:  Arthritis Rheum       Date:  1986-02

7.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Correlative studies of lymphocyte transformation and plasma protein levels in ankylosing spondylitis.

Authors:  T D Kinsella
Journal:  J Rheumatol       Date:  1979 Nov-Dec       Impact factor: 4.666

9.  Eosinophilic synovitis: clinical observations on a newly recognized subset of patients with dermatographism.

Authors:  J P Brown; M Rola-Pleszczynski; H A Ménard
Journal:  Arthritis Rheum       Date:  1986-09

10.  Hypocomplementemia in chronic idiopathic urticaria.

Authors:  D A Mathison; C M Arroyave; K N Bhat; D S Hurewitz; D J Marnell
Journal:  Ann Intern Med       Date:  1977-05       Impact factor: 25.391

View more
  3 in total

Review 1.  Hypocomplementemic urticarial vasculitis syndrome: an interdisciplinary challenge.

Authors:  Wolfgang Grotz; Hideo A Baba; Jan U Becker; Martin W Baumgärtel
Journal:  Dtsch Arztebl Int       Date:  2009-11-13       Impact factor: 5.594

Review 2.  Exceptional association of hypocomplementemic urticarial vasculitis syndrome (HUVS) and symptomatic pulmonary histoplasmosis: a case-based literature review.

Authors:  Mohammad Alomari; Laith Al Momani; Shrouq Khazaaleh; Shaden Almomani; Kinanah Yaseen; Bassam Alhaddad
Journal:  Clin Rheumatol       Date:  2019-04-13       Impact factor: 3.650

Review 3.  Is chronic urticaria more than skin deep?

Authors:  Emek Kocatürk; Clive Grattan
Journal:  Clin Transl Allergy       Date:  2019-09-25       Impact factor: 5.871

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.